## Aurobindo Pharma Limited (AUROPHARMA) Stock Analysis - December 20, 2024

This report analyzes Aurobindo Pharma Limited's stock performance and financial health based on the provided data to determine whether it's a buy, sell, or hold.

**1. Data Preprocessing:**

The provided data has been parsed and organized into the following sections:

**1.1 Company Profile:**

| Feature          | Value                     |
|-----------------|--------------------------|
| Symbol           | AUROPHARMA                |
| Company Name     | Aurobindo Pharma Limited   |
| Industry         | Pharmaceuticals           |
| Listing Date     | July 19, 2000             |
| ISIN             | INE406A01037              |


**1.2 Market Data:**

| Metric                | Value      |
|-----------------------|------------|
| Last Price            | 1,241.00   |
| Change                | -13.70     |
| % Change              | -1.09%     |
| Previous Close        | 1,254.70   |
| Open                  | 1,254.80   |
| Close                 | 1,241.70   |
| VWAP                  | 1,261.43   |
| Week High             | 1,592.00   |
| Week Low              | 958.50    |
| Sector PE             | 19.88      |
| Symbol PE             | 20.25      |
| Total Traded Volume  | 1,843,118  |
| Delivery Quantity     | 1,055,381  |
| Delivery %            | 57.26%    |
| CM Daily Volatility   | 1.71       |
| CM Annual Volatility  | 32.67      |


**1.3 Pre-Open Market Data:**

The pre-open market data shows a slight decrease in price compared to the previous close, with limited trading volume.  The final pre-open price was 1254.8, slightly higher than the opening price.

**1.4 Corporate Actions:**

| Ex-Date      | Purpose                     | Details                               |
|--------------|-----------------------------|----------------------------------------|
| 26-Aug-2024  | Annual General Meeting       |                                        |
| 30-Jul-2024  | Buy Back                     | 5,136,986 shares at a maximum of Rs.1,460 per share |
| 20-Feb-2024  | Interim Dividend            | Rs 1.50 Per Share                      |
| 20-Nov-2023  | Interim Dividend            | Rs 3 Per Share                         |
| ...          | ...                          | ...                                    |  *(Further historical dividend data available)*


**1.5 Recent Announcements:** (Selected for brevity)

* December 21, 2024: Press Release
* December 17, 2024: Loss/Duplicate Share Certificate
* ... *(Further announcements available)*


**1.6 Financial Results (Last Five Quarters):**  (Values in Rs. '000)

| Quarter Ending     | Income     | Expenditure | Profit After Tax | EPS     |
|---------------------|------------|-------------|-----------------|---------|
| 30-Sep-2024        | 294,725    | 222,350     | 53,753           | 9.21    |
| 30-Jun-2024        | 252,541    | 207,917     | 32,904           | 5.62    |
| 31-Mar-2024        | 301,700    | 223,712     | 57,867           | 9.88    |
| 31-Dec-2023        | 302,316    | 233,594     | 62,378           | 10.65   |
| 30-Sep-2023        | 273,584    | 222,606     | 41,574           | 6.48    |


**1.7 Shareholding Patterns:**

| Date          | Promoter & Promoter Group | Public |
|---------------|--------------------------|--------|
| 30-Sep-2024   | 51.82%                     | 48.18% |
| 30-Jun-2024   | 51.80%                     | 48.20% |
| 31-Mar-2024   | 51.83%                     | 48.17% |
| 31-Dec-2023   | 51.83%                     | 48.17% |
| 30-Sep-2023   | 51.83%                     | 48.17% |

Promoter holding shows minor fluctuations but remains largely stable around 51.8%.


**1.8 Board Meetings:** (Selected for brevity)

* November 9, 2024: To consider and approve Q2 and Half-Yearly financial results.
* August 10, 2024: To consider and approve Q1 financial results.
* ... *(Further board meeting details available)*


**1.9 Key Management Personnel:**

*(List of directors and their designations available in the provided data)*


**2. Key Indicators:**

**2.1 Current Price Analysis:**

* The current price (1,241.00) is below the previous close (1,254.70), indicating a downward trend.
* It's also below the week's high (1,592.00) but above the week's low (958.50).
* Pre-open activity showed a slight increase but the opening price was lower than the pre-open final price.


**2.2 Financial Performance:**

* Revenue shows some fluctuation but generally positive growth over the last five quarters.
* Profit after tax and EPS also show fluctuations, but generally positive trends.  There is a notable dip in Q1 2024.
* Detailed financial statements reveal significant information about expenses, including staff costs, raw material consumption, and other operating expenses.


**2.3 Shareholding Analysis:**

* Promoter holding is stable, indicating confidence in the company's future.


**2.4 Corporate Action Summary:**

* Recent interim dividends suggest a commitment to shareholder returns.
* The buyback of shares indicates management's belief in the company's undervalued stock.


**2.5 Volatility and Risk:**

* Daily and annual volatility metrics are available and should be considered in the context of the investor's risk tolerance.  The relatively high annual volatility suggests higher risk.


**3. Final Verdict:**

Based solely on the provided data, the recommendation is **Hold**.

**Reasoning:**

While the company shows generally positive financial performance with consistent dividend payouts and a recent share buyback, the recent price drop and relatively high volatility warrant caution.  The fluctuations in quarterly profits and the recent dip in Q1 2024 require further investigation before a strong buy recommendation can be made.  The stable promoter holding is a positive sign.  More data is needed to assess the long-term growth potential and the impact of the API business unit transfer.

**Conclusion:**

Aurobindo Pharma shows signs of financial health and a commitment to shareholder returns. However, recent price volatility and profit fluctuations suggest a wait-and-see approach is prudent.  Further analysis of the detailed financial statements and the impact of the API business unit transfer is recommended before making a definitive investment decision.
